BCL2 and B-cell chronic lymphocytic leukemia: More recently, preliminary safety and efficacy data have been presented in abstract form from the first-in-human studies of two selective BCL2 inhibitors, BGB-11417 and lisaftoclax (APG-2575), in patients with CLL/SLL and B-NHLs [20–23].